Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma

Collapse authors list.
Shah, Jatin, Shacham, Sharon, Kauffman, Michael, Daniele, Patrick, Tomaras, Dimitrios, Tremblay, Gabriel, Casasnovas, Rene-Olivier, Maerevoet, Marie, Zijlstra, Josee, Follows, George et al (show 26 more authors) , Vermaat, Joost SP, Kalakonda, Nagesh ORCID: 0000-0002-5300-1360, Goy, Andre Henri, Choquet, Sylvain, Van den Neste, Eric, Hill, Brian T, Thieblemont, Catherine, Cavallo, Federica, de la Cruz, Fatima, Kuruvilla, John, Hamad, Nada, Bouabdallah, Reda, Jager, Ulrich, Caimi, Paolo, Gurion, Ronit, Warzocha, Krzysztof, Bakhshi, Sameer, Sancho, Juan Manuel, Schuster, Michael, Egyed, Miklos, Offner, Fritz, Vasilakopoulos, Theodoros P, Samal, Priyanka, Nagy, Agnes, Ku, Matthew and Canales Albendea, Miguel Angel (2021) Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma. FUTURE ONCOLOGY, 17 (11). pp. 1295-1310.

Access the full-text of this item by clicking on the Open Access link.

Abstract

<b>Aim:</b> Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. <b>Patients & methods:</b> Functional Assessment of Cancer Therapy (FACT) - Lymphoma and EuroQoL five-dimensions five-levels data collected in the single-arm Phase IIb trial SADAL (NCT02227251) were analyzed with mixed-effects models. <b>Results:</b> Treatment responders maintained higher FACT - Lymphoma (p ≤ 0.05), FACT - General (p < 0.05) and EuroQoL five-dimensions five-levels index scores (p < 0.001) beginning in cycle 3. The estimated difference in health state utilities for treatment response and progressive disease was both statistically significant and clinically meaningful (mean difference: 0.07; p = 0.001). <b>Conclusion:</b> In patients with relapsed/refractory diffuse large B-cell lymphoma, objective response to selinexor was associated with HRQoL maintenance, reduction in disease-related HRQoL decrements and higher health utilities.

Item Type:	Article
Uncontrolled Keywords:	diffuse large B-cell lymphoma, disutility of adverse events, EQ-5D-5L, FACT-Lym, health-related quality of life, health state utility, health utility, patient reported outcomes, selinexor
Divisions:	Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User:	Symplectic Admin
Date Deposited:	07 Jul 2021 10:13
Last Modified:	18 Jan 2023 21:36
DOI:	10.2217/fon-2020-0946
Open Access URL:	https://doi.org/10.2217/fon-2020-0946
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3129125